Skip to main content
. 2019 Jul 24;37(31):2815–2824. doi: 10.1200/JCO.19.01073

FIG 2.

FIG 2.

Kaplan-Meier estimates of (A) progression-free survival (PFS), (B) time to next antilymphoma treatment (TTNLT), (C) time to next chemotherapy treatment (TTNCT), and (D) overall survival (OS) from random assignment. HR, hazard ratio.